Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejim.2020.05.009 http://scihub22266oqcxt.onion/10.1016/j.ejim.2020.05.009 32405160!7219361!32405160     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Intern+Med 2020 ; 76 (ä): 31-35 Nephropedia Template TP {{tp|p=32405160|t=2020. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia |pdf=|usr=}}{{32405160}} gab.com Text Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia JO: Eur J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32405160 #FOAvip BACKGROUND: Pneumonia with respiratory failure represents the main cause of death in COVID-19, where hyper inflammation plays an important role in lung damage. This study aims to evaluate if tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, reduces patients' mortality. METHODS: 85 consecutive patients admitted to the Montichiari Hospital (Italy) with COVID-19 related pneumonia and respiratory failure, not needing mechanical ventilation, were included if satisfying at least one among: respiratory rate >/= 30 breaths/min, peripheral capillary oxygen saturation </= 93% or PaO2/FiO2<=300 mmHg. Patients admitted before March 13th (n=23) were prescribed the standard therapy (hydroxychloroquine, lopinavir and ritonavir) and were considered controls. On March 13th tocilizumab was available and patients admitted thereafter (n=62) received tocilizumab once within 4 days from admission, plus the standard care. RESULTS: Patients receiving tocilizumab showed significantly greater survival rate as compared to control patients (hazard ratio for death, 0.035; 95% confidence interval [CI], 0.004 to 0.347; p = 0.004), adjusting for baseline clinical characteristics. Two out of 62 patients of the tocilizumab group and 11 out of 23 in the control group died. 92% and 42.1% of the discharged patients in the tocilizumab and control group respectively, recovered. The respiratory function resulted improved in 64.8% of the observations in tocilizumab patients who were still hospitalized, whereas 100% of controls worsened and needed mechanical ventilation. No infections were reported. CONCLUSIONS: Tocilizumab results to have a positive impact if used early during Covid-19 pneumonia with severe respiratory syndrome in terms of increased survival and favorable clinical course. Twit Text FOAVip Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia ????Eur J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32405160 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32405160 #FOAvip English Wikipedia <ref>{{Cite pmid|32405160}}</ref> Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia #MMPMID32405160 Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S Eur J Intern Med 2020[Jun]; 76 (ä): 31-35 PMID32405160show ga BACKGROUND: Pneumonia with respiratory failure represents the main cause of death in COVID-19, where hyper inflammation plays an important role in lung damage. This study aims to evaluate if tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, reduces patients' mortality. METHODS: 85 consecutive patients admitted to the Montichiari Hospital (Italy) with COVID-19 related pneumonia and respiratory failure, not needing mechanical ventilation, were included if satisfying at least one among: respiratory rate >/= 30 breaths/min, peripheral capillary oxygen saturation |*Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects[MESH] |*Coronavirus Infections/mortality/therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/diagnosis/drug therapy/etiology/mortality/therapy[MESH] |*Respiratory Insufficiency/etiology/mortality/therapy[MESH] |Aged[MESH] |Antiviral Agents/adverse effects[MESH] |Betacoronavirus/drug effects/isolation & purification[MESH] |COVID-19[MESH] |Dose-Response Relationship, Drug[MESH] |Early Medical Intervention/methods[MESH] |Female[MESH] |Humans[MESH] |Italy/epidemiology[MESH] |Male[MESH] |Middle Aged[MESH] |Outcome and Process Assessment, Health Care[MESH] |Receptors, Interleukin-6/*antagonists & inhibitors[MESH] |Respiration, Artificial/*methods[MESH] |Respiratory Function Tests/methods[MESH] |Retrospective Studies[MESH]Impact of low dose tocilizumab on mortality rate in patients with COVI(epmc).pdf DeepDyve Pubget Overpricing